Trial Profile

An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CX 801 (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Malignant melanoma; Renal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors CytomX Therapeutics

07 Aug 2025 According to a CytomX Therapeutics media release,dose escalation of CX-801 in combination with KEYTRUDA was initiated and Initial clinical data for the combination therapy in advanced melanoma is anticipated in 2026.
07 Aug 2025 According to a CytomX Therapeutics media release, dose escalation of CX-801 monotherapy data from this study expected in the fourth quarter of 2025.
19 May 2025 According to a CytomX Therapeutics media release, company announced that the first patient has been dosed in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com